Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

December 30, 2027

Conditions

Recurrent Platinum Resistant Epithelial Ovarian CarcinomaRecurrent Epithelial Endometrial CarcinomaRecurrent Epithelial Cervical Carcinoma

Interventions

DRUG

Sacituzumab govitecan

10mg/kg administered IV infusion on days 1 and 8 of each 21-day cycle.

Trial Locations (1)

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT06865677 - Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas | Biotech Hunter | Biotech Hunter